GR20060100496A - ΛΙΠΟΣΩΜΑΤΙΚΑ ΕΓΚΑΨΥΛΙΩΜΕΝΟΙ ΦΟΡΕΙΣ-ΥΒΡΙΔΙΟΥ ΑΔΕΝΟΙΟΥ - ΙΟΥ SEMLIKI FOREST (SFV), ΠΟΥ ΦΕΡΕΙ ΚΑΤΑΣΚΕΥΑΣΜΑΤΑ RNAi ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΑ ΓΟΝΙΔΙΑ ΠΟΥ ΧΡΗΣΙΜΟΠΟΙΟΥΝΤΑΙ ΕΝΑΝΤΙΟΝ ΣΤΟΧΩΝ ΚΑΡΚΙΝΟΥ ΚΑΙ ΑΛΛΩΝ ΑΣΘΕΝΕΙΩΝ - Google Patents

ΛΙΠΟΣΩΜΑΤΙΚΑ ΕΓΚΑΨΥΛΙΩΜΕΝΟΙ ΦΟΡΕΙΣ-ΥΒΡΙΔΙΟΥ ΑΔΕΝΟΙΟΥ - ΙΟΥ SEMLIKI FOREST (SFV), ΠΟΥ ΦΕΡΕΙ ΚΑΤΑΣΚΕΥΑΣΜΑΤΑ RNAi ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΑ ΓΟΝΙΔΙΑ ΠΟΥ ΧΡΗΣΙΜΟΠΟΙΟΥΝΤΑΙ ΕΝΑΝΤΙΟΝ ΣΤΟΧΩΝ ΚΑΡΚΙΝΟΥ ΚΑΙ ΑΛΛΩΝ ΑΣΘΕΝΕΙΩΝ

Info

Publication number
GR20060100496A
GR20060100496A GR20060100496A GR20060100496A GR20060100496A GR 20060100496 A GR20060100496 A GR 20060100496A GR 20060100496 A GR20060100496 A GR 20060100496A GR 20060100496 A GR20060100496 A GR 20060100496A GR 20060100496 A GR20060100496 A GR 20060100496A
Authority
GR
Greece
Prior art keywords
sequence
sfv
adenoviral
forest virus
semliki forest
Prior art date
Application number
GR20060100496A
Other languages
English (en)
Inventor
Παρθενιος Μπουλικας
Michael Roberts
Original Assignee
Παρθενιος Μπουλικας
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Παρθενιος Μπουλικας filed Critical Παρθενιος Μπουλικας
Priority to GR20060100496A priority Critical patent/GR20060100496A/el
Priority to EP07804505A priority patent/EP2121945A2/en
Priority to PCT/GR2007/000044 priority patent/WO2008026015A2/en
Priority to US12/439,636 priority patent/US20100008977A1/en
Priority to CA002662150A priority patent/CA2662150A1/en
Publication of GR20060100496A publication Critical patent/GR20060100496A/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C12N15/8613—Chimaeric vector systems comprising heterologous sequences for production of another viral vector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Birds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Εν συντομία, η εφεύρεση αφορά ένα φορέα εκφράσεωςγονιδίου υβριδικού Ιού αδενοϊού - Semliki Forest (SFV) ο οποίος χαρακτηρίζεται εκ του ότι περιλαμβάνει τουλάχιστον τα επόμενα στοιχεία προσανατολισμένα από το 5' έως το 3', δηλαδή :(i) μια πρώτη αλυσίδα αδενοϊικής προελεύσεως η οποία περιέχει μια πρώτη ανεστραμμένη τερματική επαναλαμβανομένη σειρά (ITR) και μια σειρά σήματος δια τη συσκευασία τουαδενοϊού (ιι) μια σειρά που αντιστοιχεί σε έναν ειδικό ιστό ή ένα διεγειρόμενο προωθητή (iv) μια αλυσίδα cDNA που προέρχεται από SFV, η σειρά της οποίας είναι εν μέρει συμπληρωματική προς ένα SFV RNAτο οποίο είναι μεταλλαγμένο σε δύο σημεία εις τηνπεριοχή nsP1-4 προς ελάττωση της τοξικότητος, πουπεριλαμβάνει τουλάχιστον μια σειρά που δίδει τον κώδικα δια ένα τουλάχιστον εξωγενή βρόγχο φουρκέτας (καρφίτσα για μαλλιά) ενός κοντού παρεμβαίνοντοςRNA (v) μια σειρά πολυαδενυλιώσεως και (vi) μια δευτέρα αδενοϊική σειρά που παραλείπεται εις τις περιοχές Ε3 και Ε2 ή Ε4 έως την 3' αδενοϊική ανεστραμμένη τερματική σειρά επαναλήψεως (ITR). Η εφεύρεση κατά προτίμηση αφορά έναν υβριδικό αδενοϊικό SFVφορέα ο οποίος περιέχει ως εξωγενή βρόγχο καρφίτσας μαλλιών ενός κοντού παρεμβαίνοντος RNA, miRNA ήdsRNA και κατά ακόμη μεγαλυτέρα προτίμηση σειρές παρεμβάσεως RNA που κατευθύνονται προς τα γονίδια που δίδουν τον κώδικα κυκλινών A,B,C,D και E, DNA πολυμερασών άλφα,βήτα,γάμμα και δέλτα, DNA λιπασώνκαι DNA τοποϊσομερασών, γονιδίων που δίδουν τον κώδικα βασικών στοιχείων κυτταρικού μεταβολισμού ATPασών, γλυκολυτικών ενζύμων και συστατικών αλυσίδος μεταφοράς ηλεκτρονίου μιτοχονδριακής μεμβράνης και προς τυροσίνο κινάσες ενεργοποιημένες με ογκογονίδια και προς δέκτες τυροσίνο κινάσης, EGFR, Ras,Raf, c-myc και μετάλλαξη p53. Επίσης περιγράφεταιμια νέα μέθοδος δια την κατασκευή νέων αδενοϊών δια ανασυνδυασμού ενός πλασμιδίου οχήματος με ένα πλασμίδιο αδενοϊικών σκελετών που παραλείπεται εις το Ε1, Ε3, Ε2 και Ε4.
GR20060100496A 2006-09-01 2006-09-01 ΛΙΠΟΣΩΜΑΤΙΚΑ ΕΓΚΑΨΥΛΙΩΜΕΝΟΙ ΦΟΡΕΙΣ-ΥΒΡΙΔΙΟΥ ΑΔΕΝΟΙΟΥ - ΙΟΥ SEMLIKI FOREST (SFV), ΠΟΥ ΦΕΡΕΙ ΚΑΤΑΣΚΕΥΑΣΜΑΤΑ RNAi ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΑ ΓΟΝΙΔΙΑ ΠΟΥ ΧΡΗΣΙΜΟΠΟΙΟΥΝΤΑΙ ΕΝΑΝΤΙΟΝ ΣΤΟΧΩΝ ΚΑΡΚΙΝΟΥ ΚΑΙ ΑΛΛΩΝ ΑΣΘΕΝΕΙΩΝ GR20060100496A (el)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GR20060100496A GR20060100496A (el) 2006-09-01 2006-09-01 ΛΙΠΟΣΩΜΑΤΙΚΑ ΕΓΚΑΨΥΛΙΩΜΕΝΟΙ ΦΟΡΕΙΣ-ΥΒΡΙΔΙΟΥ ΑΔΕΝΟΙΟΥ - ΙΟΥ SEMLIKI FOREST (SFV), ΠΟΥ ΦΕΡΕΙ ΚΑΤΑΣΚΕΥΑΣΜΑΤΑ RNAi ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΑ ΓΟΝΙΔΙΑ ΠΟΥ ΧΡΗΣΙΜΟΠΟΙΟΥΝΤΑΙ ΕΝΑΝΤΙΟΝ ΣΤΟΧΩΝ ΚΑΡΚΙΝΟΥ ΚΑΙ ΑΛΛΩΝ ΑΣΘΕΝΕΙΩΝ
EP07804505A EP2121945A2 (en) 2006-09-01 2007-09-03 Liposomally encapsulated hybrid adenovirus-semliki forest virus (sfv) vectors carrying rnai constructs and therapeutic genes for use against cancer targets and other diseases
PCT/GR2007/000044 WO2008026015A2 (en) 2006-09-01 2007-09-03 Liposomally encapsulated hybrid adenovirus-semliki forest virus (sfv) vectors carrying rnai constructs and therapeutic genes for use against cancer targets and other diseases
US12/439,636 US20100008977A1 (en) 2006-09-01 2007-09-03 Liposomally encapsulated hybrid adenovirus-semliki forest virus (sfv) vectors carrying rnai constructs and therapeutic genes for use against cancer targets and other diseases
CA002662150A CA2662150A1 (en) 2006-09-01 2007-09-03 Liposomally encapsulated hybrid adenovirus-semliki forest virus (sfv) vectors carrying rnai constructs and therapeutic genes for use against cancer targets and other diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20060100496A GR20060100496A (el) 2006-09-01 2006-09-01 ΛΙΠΟΣΩΜΑΤΙΚΑ ΕΓΚΑΨΥΛΙΩΜΕΝΟΙ ΦΟΡΕΙΣ-ΥΒΡΙΔΙΟΥ ΑΔΕΝΟΙΟΥ - ΙΟΥ SEMLIKI FOREST (SFV), ΠΟΥ ΦΕΡΕΙ ΚΑΤΑΣΚΕΥΑΣΜΑΤΑ RNAi ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΑ ΓΟΝΙΔΙΑ ΠΟΥ ΧΡΗΣΙΜΟΠΟΙΟΥΝΤΑΙ ΕΝΑΝΤΙΟΝ ΣΤΟΧΩΝ ΚΑΡΚΙΝΟΥ ΚΑΙ ΑΛΛΩΝ ΑΣΘΕΝΕΙΩΝ

Publications (1)

Publication Number Publication Date
GR20060100496A true GR20060100496A (el) 2008-04-15

Family

ID=39136312

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20060100496A GR20060100496A (el) 2006-09-01 2006-09-01 ΛΙΠΟΣΩΜΑΤΙΚΑ ΕΓΚΑΨΥΛΙΩΜΕΝΟΙ ΦΟΡΕΙΣ-ΥΒΡΙΔΙΟΥ ΑΔΕΝΟΙΟΥ - ΙΟΥ SEMLIKI FOREST (SFV), ΠΟΥ ΦΕΡΕΙ ΚΑΤΑΣΚΕΥΑΣΜΑΤΑ RNAi ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΑ ΓΟΝΙΔΙΑ ΠΟΥ ΧΡΗΣΙΜΟΠΟΙΟΥΝΤΑΙ ΕΝΑΝΤΙΟΝ ΣΤΟΧΩΝ ΚΑΡΚΙΝΟΥ ΚΑΙ ΑΛΛΩΝ ΑΣΘΕΝΕΙΩΝ

Country Status (5)

Country Link
US (1) US20100008977A1 (el)
EP (1) EP2121945A2 (el)
CA (1) CA2662150A1 (el)
GR (1) GR20060100496A (el)
WO (1) WO2008026015A2 (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2248903A1 (en) * 2009-04-29 2010-11-10 Universitat Autònoma De Barcelona Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages
EP2508607A1 (en) * 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
EP2811023B1 (en) * 2012-02-01 2018-10-24 Postech Academy-Industry Foundation Vector simultaneously expressing dodecameric trail and hsv-tk suicide genes, and anticancer stem cell therapeutic agent using same
AU2014236207B2 (en) 2013-03-14 2019-05-23 Salk Institute For Biological Studies Oncolytic adenovirus compositions
ES2523016B1 (es) * 2013-05-20 2015-09-09 3P Biopharmaceuticals Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes
HUE053033T2 (hu) * 2013-06-19 2021-06-28 Apse Llc Hidrolázoknak ellenálló kapszidokat alkalmazó készítmények és eljárások
CN117384961A (zh) 2016-02-23 2024-01-12 萨克生物研究学院 对病毒动力学影响最小的治疗性腺病毒中的外源基因表达
CA3013637A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
WO2018111767A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
CN109806390A (zh) * 2019-01-07 2019-05-28 康希诺生物股份公司 一种SamRNA疫苗及其制备方法
CN113549652A (zh) * 2021-07-21 2021-10-26 华农（肇庆）生物产业技术研究院有限公司 SFV-helper质粒、pSFVCs-LacZ病毒样颗粒及其制备方法和应用
CN115094088A (zh) * 2022-04-19 2022-09-23 华南农业大学 一种pSFV-flagX-CMV复制子质粒、制备方法和鸡尾酒混合疫苗

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814618A (en) * 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US5464758A (en) * 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5894060A (en) * 1996-06-28 1999-04-13 Boulikas; Teni Cloning method for trapping human origins of replication
US6030956A (en) * 1996-10-24 2000-02-29 Boulikas; Teni Combination gene therapy for human cancers

Also Published As

Publication number Publication date
WO2008026015A2 (en) 2008-03-06
EP2121945A2 (en) 2009-11-25
US20100008977A1 (en) 2010-01-14
WO2008026015A3 (en) 2008-07-17
CA2662150A1 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
GR20060100496A (el) ΛΙΠΟΣΩΜΑΤΙΚΑ ΕΓΚΑΨΥΛΙΩΜΕΝΟΙ ΦΟΡΕΙΣ-ΥΒΡΙΔΙΟΥ ΑΔΕΝΟΙΟΥ - ΙΟΥ SEMLIKI FOREST (SFV), ΠΟΥ ΦΕΡΕΙ ΚΑΤΑΣΚΕΥΑΣΜΑΤΑ RNAi ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΑ ΓΟΝΙΔΙΑ ΠΟΥ ΧΡΗΣΙΜΟΠΟΙΟΥΝΤΑΙ ΕΝΑΝΤΙΟΝ ΣΤΟΧΩΝ ΚΑΡΚΙΝΟΥ ΚΑΙ ΑΛΛΩΝ ΑΣΘΕΝΕΙΩΝ
Yoo et al. VEGF-specific short hairpin RNA–expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth
Nogawa et al. Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer
Grimm et al. Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver
Ramchandani et al. Nanoparticle delivery of miR-708 mimetic impairs breast cancer metastasis
CN103555722B (zh) 利用不对称双链rna特异性抑制kras的方法和组合物
Aoki et al. RNA interference may be more potent than antisense RNA in human cancer cell lines
WO2004033620A3 (en) Methods and compositions for therapeutic use of rna interference
Hadas et al. Modified mRNA as a therapeutic tool to induce cardiac regeneration in ischemic heart disease
WO2008026946A2 (en) Compositions and methods for the treatment and prevention of neoplastic disorders
CN104619844A (zh) 靶向p53的双链寡核苷酸分子及其使用方法
Saha et al. Vector-delivered artificial miRNA effectively inhibited replication of Chikungunya virus
US11596685B2 (en) Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids
Tong Small RNAs and non-small cell lung cancer
Bhomia et al. Artificial microRNAs can effectively inhibit replication of Venezuelan equine encephalitis virus
Peng et al. Alpha-fetoprotein promoter-driven Cre/LoxP-switched RNA interference for hepatocellular carcinoma tissue-specific target therapy
Arbuthnot et al. Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma
Zhang et al. shRNA-armed conditionally replicative adenoviruses: a promising approach for cancer therapy
CN105189541A (zh) 用于通过双链rna特异性抑制ckap5的方法和组合物
Wu et al. Nerve injection of viral vectors efficiently transfers transgenes into motor neurons and delivers RNAi therapy against ALS
US20050043263A1 (en) Use of double-stranded ribonucleic acid for inducing cell lysis
Kubo et al. Antitumor effect of palmitic acid‐conjugated Dsi RNA for colon cancer in a mouse subcutaneous tumor model
Kubo et al. In Vivo RNAi Efficacy of Palmitic Acid‐Conjugated Dicer‐Substrate siRNA in a Subcutaneous Tumor Mouse Model
Gomes de Souza et al. Different gene therapy strategies: A overview for prostate cancer
CN101011575B (zh) 预防和治疗动脉粥样硬化病的rna干扰药物

Legal Events

Date Code Title Description
ML Lapse due to non-payment of fees

Effective date: 20130404